Category Patents/Designs/Trade Secrets

Nagoya Protocol Implications For Health, Flu Genetic Data On WHO Board Agenda

The World Health Organization recently published its analysis about the public health implications of the Nagoya Protocol on genetic resources access and benefit-sharing, and in particular how it affects the sharing of pathogens, like influenza viruses. The findings are set to be discussed at this month’s WHO Executive Board meeting. Also to be discussed is an experts group review of the WHO pandemic influenza framework, and in particular its conclusion that the framework should be amended to match scientific progress.

EU Study Recommends FRAND Clarification, More Coordination On 5G

The rapid development of information and communication technologies, and the need for greater interconnectivity driven by the Internet of Things has created a variety of standard-essential patent (SEP) owners and implementers with different business models, and for more diverse licensing practices, the European Commission Joint Research Centre says in a new study. This has made it harder to agree on an interpretation of FRAND licensing principles, something European policymakers must clarify in order to meet key digital single market and other goals, it says.

ARIPO Lines Up IP Enhancing Activities For 2017

CAPE TOWN, South Africa – From establishing training schemes, exchange expertise, sharing research, and helping members acquire and develop technology related to intellectual property and shape copyright associated rights, the African Regional Intellectual Property Organization (ARIPO) has set targets for implementation in 2017.

After 15 Years In WTO, China Still Weak On Many IP Rights Rules, US Says

Innovation and intellectual property rights have set the United States apart from competitors in recent history, and China seems intent on closing that gap any way it can. A US trade office report out this week on China’s compliance with World Trade Organization rules 15 years after accession show the magnitude of China’s continuing compliance problems related to intellectual property rights.

Expensive Medicines Increase The Pressure

When Gilead brought its new antiviral medicine – Sovaldi – for the treatment of Hepatitis C to the US market for USD 84,000, it triggered a storm of protest. Demand for this revolutionary treatment was so high that the price (despite reductions) became an enormous burden on the American healthcare system. Although the product is cheaper in Switzerland at CHF 48 307, treatment is rationed for reasons of cost.